Active substanceCarnitineCarnitine
Similar drugsTo uncover
  • Carnitine chloride
    concentrate d / infusion 
  • Dosage form: & nbspconcentrate for solution for infusion
    Composition:

    1 ml of the solution contains:

    active substance: carnitine chloride 100 mg;

    adjuvant: water for injection up to 1 ml.

    Description:Transparent colorless or almost colorless liquid.
    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    A.16.A.A.01   Levocarnitine

    Pharmacodynamics:

    Carnitine is a metabolic remedy. The drug stimulates metabolic processes, participating in various links of energy metabolism, has anabolic, antihypoxic and antithyroid effect, activates lipid metabolism, stimulates regeneration, increases appetite. Carnitine - a natural substance, related to vitamins of group B. It is a cofactor of metabolic processes that ensure the maintenance of CoA activity. Reduces the basal metabolism, slows down the breakdown of protein and carbohydrate molecules. Promotes penetration through the membranes of mitochondria and the cleavage of long-chain fatty acids (palmitic and others) with the formation of acetyl-CoA, necessary to ensure the activity of pyruvate carboxylase in the process of gluconeogenesis, the formation of ketone bodies, the synthesis of choline and its ethers,oxidative phosphorylation and the formation of ATP. Mobilizes fat (the presence of three labile methyl groups) from fat stores. Competitively superseding glucose, includes a fatty acid metabolic shunt whose activity is not limited by oxygen (in contrast to aerobic glycolysis), in connection with which the drug is effective in conditions of acute hypoxia (in the so-called brain) and other critical conditions. It has neurotrophic action, inhibits apoptosis, limits the affected area and restores the structure of the nervous tissue. Normalizes protein and fat metabolism, increased basal metabolism in hyperthyroidism (being a partial antagonist of thyroxin). The drug restores the alkaline blood reserve, does not affect the blood coagulation system, reduces the formation of keto acids, increases the resistance of tissues to the effect of toxic decay products, activates aerobic processes and depresses anaerobic glycolysis, has antihypoxic properties, stimulates and accelerates reparative processes.

    Pharmacokinetics:

    After intravenous administration, after 3 hours disappears from the blood. Easily penetrates into the liver and myocardium, more slowly - into the muscles. It is excreted by the kidneys mainly in the form of acyl esters.

    Indications:

    - Acute disorders of cerebral circulation - ischemic stroke (in acute, subacute and recovery periods), transient ischemic attack - as part of complex therapy;

    - encephalopathy;

    - traumatic and toxic lesions of the brain.

    Contraindications:

    - Hypersensitivity to carnitine;

    - age to 18 years (no special studies have been conducted in children).

    Pregnancy and lactation:

    Special studies of use during pregnancy and during breastfeeding were not conducted. The decision to use should be taken, assessing the ratio of possible risks to the child and benefits for the mother.

    Dosing and Administration:

    The drug is administered intravenously drip slowly (no more than 60 drops per minute). Before the introduction, the contents of one or two ampoules - 5-10 ml (0.5-1 g) - are diluted in 200 ml of 0.9% sodium chloride solution for injection.

    In acute disorders of cerebral circulation, 1 g once a day is prescribed for the first three days, and 0.5 g daily for 7 days. After 10-12 days, repeated courses are recommended - 0.5 g once a day for 3-5 days.

    When prescribing the drug in subacute and recovery periods,with discirculatory encephalopathy and various brain lesions, the patient is administered 0.5-1 g (1-2 ampoules) of the drug once a day for 3-5 days. If necessary, after 12-14 days, appoint a second course.

    Side effects:

    Allergic reactions are possible.

    In patients with uremia, muscle weakness is possible.

    With rapid administration (80 drops per minute or more), pain can occur along the veins that pass with a decrease in the rate of administration.

    In patients with a modified venous wall, as a result of prolonged intravenous infusions, the irritating effect of carnitine is possible, which decreases substantially with a greater degree of dilution.

    Overdose:

    Cases of overdose are unknown.

    Interaction:

    Glucocorticosteroids when combined with carnitine contribute to its accumulation in tissues (except for the liver).

    Anabolic agents enhance the effect.

    Form release / dosage:

    Concentrate for the preparation of a solution for infusions of 100 mg / ml.

    Packaging:

    In ampoules of 5 ml.

    5 ampoules per contour cell pack.

    1 or 2 contour squares with instructions for use in a pack of cardboard box.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    4 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N002672 / 01
    Date of registration:20.06.2008 / 26.12.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:FGBU RKNPK ROSZDRAVA - EPMPP FGBU RKNPK ROSZDRAVA - EPMPP Russia
    Manufacturer: & nbsp
    Representation: & nbspFGU RKNPK ROSZDRAVA - EPMPP FGU RKNPK ROSZDRAVA - EPMPP Russia
    Information update date: & nbsp14.12.2017
    Illustrated instructions
      Instructions
      Up